Development of inhalable platelet-based therapy for treatment of acute lung injury

开发用于治疗急性肺损伤的可吸入血小板疗法

• 批准号: 2748838
• 金额: --
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2748838
• 关键词: Development; inhalable; platelet; based; therapy

Patients with lung injury arising from trauma or infection can develop acute respiratory distress syndrome and pulmonary oedema with a high mortality rate. Platelet rich plasma (PRP), produced by concentrating platelets from patients own blood, is a therapy that is proving highly effective in clinical trials for other tissue injuries that require regeneration, e.g. diabetic ulcers. This project will investigate the hypothesis that a regenerative PRP product can be administered to the lungs by inhalation to treat acute lung injury. Training will be provided in collaborative bioscience and pharmaceutical development to design a novel therapy and develop it towards patient benefit. The project will be developed in phases. The first year will provide technical training and confirmation of preliminary data on PRP production techniques and in vitro models/bioassays to guide product development. Year 2 will focus on product characterisation and developing aerosol delivery systems, along with exploratory in vivo studies. A 3-month placement with Biotherapy Services will provide training in Disease Area Mapping to understand the clinical need and health impacts of the novel therapy. By year 3 product prototypes will be ready for confirmatory safety and efficacy in a pre-clinical disease model. In year 4 a proof-of-concept study will be performed to demonstrate the efficacy of the optimised inhaled PRP in an in vivo model of lung injury. The line-of-sight to the clinic will be strongly embedded in project goal setting and student training. This will be led by Biotherapy Services and will run alongside laboratory investigations.

创伤或感染引起的肺损伤患者可发展为急性呼吸窘迫综合征和肺水肿，死亡率高。富血小板血浆（PRP）是通过从患者自身血液中浓缩血小板而产生的，是一种在临床试验中被证明对其他需要再生的组织损伤（例如糖尿病溃疡）非常有效的疗法。本项目将研究再生PRP产品可以通过吸入给予肺部以治疗急性肺损伤的假设。将提供合作生物科学和药物开发方面的培训，以设计一种新的治疗方法，并将其发展为对患者有益的方法。 该项目将分阶段开发。第一年将提供技术培训和确认PRP生产技术和体外模型/生物测定的初步数据，以指导产品开发。第二年将专注于产品特性和气雾剂输送系统的开发，沿着探索性体内研究。为期3个月的生物治疗服务将提供疾病区域映射的培训，以了解新疗法的临床需求和健康影响。到第3年，产品原型将准备好在临床前疾病模型中确认安全性和有效性。在第4年，将进行概念验证研究，以证明优化的吸入PRP在肺损伤体内模型中的疗效。 视线到诊所将强烈嵌入项目目标设定和学生培训。这将由生物治疗服务公司领导，并将与实验室调查一起进行。